Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Mineralys Therapeutics Inc (MLYS)

Mineralys Therapeutics Inc (MLYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) GlobeNewswire - Sat May 30, 10:15AM CDT

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease – – In participants...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference GlobeNewswire - Wed May 27, 7:00AM CDT

RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) GlobeNewswire - Mon May 18, 3:05PM CDT

– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease – RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) --...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire - Wed May 6, 3:05PM CDT

– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 06,...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue May 5, 4:34PM CDT

RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Reports First Quarter Results With Lorundrostat Trial Data Still Pending Barchart - Tue May 5, 4:25PM CDT

Barchart Research What to Expect from MLYS Earnings MLYS Generated May 5, 2026 Current Price $29.28 EPS Estimate $$-0.51 Consensus Rating Strong Buy Average Move 6.61% Mineralys Therapeutics Reports First...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference GlobeNewswire - Tue May 5, 7:00AM CDT

RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026 GlobeNewswire - Wed Apr 29, 3:05PM CDT

RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer GlobeNewswire - Tue Mar 24, 7:00AM CDT

RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Mar 16, 3:05PM CDT

RADNOR, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)

Barchart Exclusives

This High-Yield Home Improvement Stock Just Hiked Its Dividend by 4.2% Barchart - Mon Jun 1, 6:30PM CDT
Lowe’s Companies raised its quarterly dividend by 4.2% to $1.25 per share, marking its 55th consecutive year of increases and reinforcing its status as a Dividend King amid a challenging housing market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.